Evidence map›Paper›PMID 31507634›Full record

ArticleFrontiers in genetics2019

Two Novel

Vita Setrajcic Dragos, Ana Blatnik, Gasper Klancar, Vida Stegel, Mateja Krajc, Olga Blatnik, Srdjan Novakovic

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. A Novel GermlineGenes · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Vita Setrajcic DragosDepartment of Molecular Diagnostics, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
Ana BlatnikCancer Genetics Clinic, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
Gasper KlancarDepartment of Molecular Diagnostics, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
Vida StegelDepartment of Molecular Diagnostics, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
Mateja KrajcCancer Genetics Clinic, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
Olga BlatnikDepartment of Pathology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
Srdjan NovakovicDepartment of Molecular Diagnostics, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
Institute of Oncology Ljubljana · SI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurofibromatosis type I (NF1) is one of the most common autosomal dominant disorders, since the estimated incidence is one in 3,500 births. In this study, we present bioinformatical and functional characterization of two novel splicing

Indexed as

functional analysismRNAneurofibromatosis type INF1NGSsplicingsplicing alterationvariant of uncertain significance

Identifiers

PMID31507634
PMCPMC6714493
OpenAlexW2958173109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.